Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study

Ajmani Ajay Kumar; Agrawal Aparna; Prasad B. L. N.; Basu Indraneel; Shembalkar Jayashree; Manikanth Neeraj; Subrahmanyam K. A. V.; Srinivasa M.; Chawla Manoj; Srivastava Manoj Kumar; Jebasingh Felix; Achappa Basavaprabhu; Agrawal R. P.; Pulichikkat Rakesh K.; Meena Ramdhan; Bhatia Shailaja; Gupta Sandeep Kumar; Dange Amol; Srivastava Ambrish; Trailokya Abhijit; Shahavi Vinayaka; Shende Sachin

首页> 外文期刊>Diabetes research and clinical practice >Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study

【24h】

Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study

机译：Evogliptin与SitaGlittin的疗效和安全性作为印度患者的患者患者患有2型糖尿病患者的加入治疗与二甲双胍相当不充分控制：24周随机化，双盲，非劣等，进化印度研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: This study aimed to assess efficacy and safety of evogliptin versus sitagliptin, when added to background metformin therapy in Indian patients with uncontrolled type 2 diabetes.

机译：目的：本研究旨在评估Evogliptin与SitaGliptin的疗效和安全性，当印度患者不受控制的2型糖尿病患者的背景二甲双胍治疗时。

著录项

来源
《Diabetes research and clinical practice》 |2019年第2019期|共8页
作者
Ajmani Ajay Kumar; Agrawal Aparna; Prasad B. L. N.; Basu Indraneel; Shembalkar Jayashree; Manikanth Neeraj; Subrahmanyam K. A. V.; Srinivasa M.; Chawla Manoj; Srivastava Manoj Kumar; Jebasingh Felix; Achappa Basavaprabhu; Agrawal R. P.; Pulichikkat Rakesh K.; Meena Ramdhan; Bhatia Shailaja; Gupta Sandeep Kumar; Dange Amol; Srivastava Ambrish; Trailokya Abhijit; Shahavi Vinayaka; Shende Sachin;
展开▼
作者单位

Dr BL Kapur Super Special Hosp New Delhi India;

Lady Hardinge Med Coll &

Hosp New Delhi India;

Rajiv Gandhi Inst Med Sci Srikakulam India;

Popular Hosp Varanasi Uttar Pradesh India;

Getwell Hosp &

Res Inst Nagpur Maharashtra India;

Govt Med Coll Parippally Kerala India;

King George Hosp Andhra Med Coll Vishakhapatnam India;

Mysore Med Coll &

Res Inst Krishna Rajendra Hosp Mysore Karnataka India;

BSES Municipal Gen Hosp Mumbai Maharashtra India;

Om Surg Ctr Matern Home Varanasi Uttar Pradesh India;

Christian Med Coll &

Hosp Vellore Tamil Nadu India;

Kasturba Med Coll &

Hosp Mangalore India;

SP Med Coll &

PBM Hosp Bikaner India;

Sree Narayana Inst Med Sci Kochi Kerala India;

SR Kalla Mem Gastro &

Gen Hosp Jaipur Rajasthan India;

Medipoint Hosp Put Ltd Pune Maharashtra India;

KRM Hosp &

Res Ctr Lucknow Uttar Pradesh India;

Lifepoint Multispecialty Hosp Pune Maharashtra India;

Alkem Labs Ltd Mumbai Maharashtra India;

Alkem Labs Ltd Mumbai Maharashtra India;

Alkem Labs Ltd Mumbai Maharashtra India;

Alkem Labs Ltd Mumbai Maharashtra India;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词
Evogliptin; Dipeptidyl peptidase-4 inhibitor; Type 2 diabetes mellitus; Sitagliptin;

机译：evogliptin;二肽肽肽酶-4抑制剂;2型糖尿病;SITAGLIPTIN;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study [J] . Ajmani Ajay Kumar, Agrawal Aparna, Prasad B. L. N., Diabetes research and clinical practice . 2019,第期

机译：Evogliptin与SitaGlittin的疗效和安全性作为印度患者的患者患者患有2型糖尿病患者的加入治疗与二甲双胍相当不充分控制：24周随机化，双盲，非劣等，进化印度研究
2. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension [J] . Hong Sang-Mo, Park Cheol-Young, Hwang Dong-Min, Diabetes, obesity & metabolism . 2017,第5期

机译：添加evogliptin对二甲双胍治疗2型糖尿病患者的evogliptin对SitaGlittin的功效和安全性：24周随机，控制试验，开放标签延伸
3. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study) [J] . Ahn Chang Ho, Han Kyung Ah, Yu Jae Myung, Diabetes, obesity & metabolism . 2017,第5期

机译：二肽素肽酶-4抑制剂的Gemiglitin的功效和安全性，2型糖尿病患者与二甲双胍和磺酰脲的组合治疗不充分控制：24周，多期，随机，双盲，安慰剂对照研究（Troica研究的）
4. Changes of skin temperature of parts of the body and serum asymmetric dimethylarginine (ADMA) in type-2 diabetes mellitus Indian patients [C] . Anburajan M, Sivanandam S, Bidyarasmi S, 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2011

机译：印度2型糖尿病患者身体局部皮肤温度和血清不对称二甲基精氨酸（ADMA）的变化
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter randomized open-label non-inferiority trial [O] . Hidetaka Yokoh, Kazuki Kobayashi, Yasunori Sato, 2015

机译：在单独使用二甲双胍或吡格列酮控制不充分的日本2型糖尿病患者中二肽基肽酶4抑制剂西他列汀与α-葡萄糖苷酶抑制剂相比的疗效和安全性（采用西他列汀1控制糖尿病的最终联合疗法研究）：随机开放标签非劣效性试验
7. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled non-inferiority trial [O] . NAUCK MA, DEL PRATO S, MEIER JJ, 2011

机译：达格列净与格列吡嗪作为二甲双胍血糖控制不足的2型糖尿病患者的附加治疗：一项随机，为期52周，双盲，主动控制的非劣效性试验

Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study

摘要

著录项

相似文献

相关主题

期刊订阅